Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age

(2018) Susan J. Ermlich et al.   VACCINE

Direct and Indirect Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Carriage in a Cluster Randomized Trial

(2017) Arto A. Palmu et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis

(2017) Gerhard Falkenhorst et al.   PLoS One

Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study

(2017) Ángela Domínguez et al.   PLoS One

Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden

(2016) Ilias Galanis et al.   EUROPEAN RESPIRATORY JOURNAL

Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay

(2016) Mathias W. Pletz et al.   VACCINE

Serotype 3 Remains the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2012–2014) Despite Continued Reductions in Other 13-Valent Conjugate Vaccine Serotypes

(2016) Andreia N. Horácio et al.   Frontiers in Microbiology

Effectiveness of the 10-Valent Pneumococcal NontypeableHaemophilus influenzaeProtein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland

(2016) Timo Vesikari et al.   Journal of the Pediatric Infectious Diseases Society

Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia

(2015) Chamira Rodrigo et al.   EUROPEAN RESPIRATORY JOURNAL

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

(2015) Pauline A Waight et al.   LANCET INFECTIOUS DISEASES

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

(2015) Marc J.M. Bonten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Tolerability and Immunogenicity of 15-valent Pneumococcal Conjugate Vaccine in Toddlers Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine

(2015) Ajoke Sobanjo-ter Meulen et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Decline in Pneumococcal Nasopharyngeal Carriage of Vaccine Serotypes After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Atlanta, Georgia

(2015) Ankita P. Desai et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Changes in Pneumococcal Serotypes and Antimicrobial Resistance after Introduction of the 13-Valent Conjugate Vaccine in the United States

(2014) Sandra S. Richter et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Early Impact of 13-Valent Pneumococcal Conjugate Vaccine on Community-Acquired Pneumonia in Children

(2014) F. Angoulvant et al.   CLINICAL INFECTIOUS DISEASES

Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis

(2014) Lone Simonsen et al.   Lancet Respiratory Medicine

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012

(2013) Walter H.B. Demczuk et al.   CANADIAN JOURNAL OF MICROBIOLOGY

Pneumococcal infection in adults: burden of disease

(2013) J.J.C. Drijkoningen et al.   CLINICAL MICROBIOLOGY AND INFECTION

Distribution of 13-Valent Pneumococcal Conjugate Vaccine Streptococcus pneumoniae Serotypes in US Adults Aged >=50 Years With Community-Acquired Pneumonia

(2013) R. L. Sherwin et al.   JOURNAL OF INFECTIOUS DISEASES

U.S. Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination

(2013) Marie R. Griffin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Early Trends for Invasive Pneumococcal Infections in Children After the Introduction of the 13-valent Pneumococcal Conjugate Vaccine

(2013) Sheldon L. Kaplan et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites

(2013) Daniel R. Feikin et al.   PLOS MEDICINE

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial

(2012) Arto A Palmu et al.   LANCET

Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe

(2011) David S Fedson et al.   Expert Review of Vaccines

Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease

(2010) Inci Yildirim et al.   VACCINE

Optimization and Validation of a Multiplex, Electrochemiluminescence-Based Detection Assay for the Quantitation of Immunoglobulin G Serotype-Specific Antipneumococcal Antibodies in Human Serum

(2009) R. D. Marchese et al.   Clinical and Vaccine Immunology

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

(2009) Tamara Pilishvili et al.   JOURNAL OF INFECTIOUS DISEASES

Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: A matched case–control study

(2009) Angel Vila-Corcoles et al.   VACCINE